|[February 12, 2014]
XenoPort to Release Fourth Quarter and Year-End Financial Results on February 20, 2014
SANTA CLARA, Calif. --(Business Wire)--
XenoPort, Inc. (Nasdaq:XNPT) announced today that it will release its
fourth quarter financial results on February 20, 2014 at approximately
4:30 p.m. Eastern Time. The company will host a conference call at 5:00
p.m. Eastern Time that same day. A replay of the call will be available
for one week following the event.
To access the conference call via the Internet, go to www.XenoPort.com.
Please join the call at least 15 minutes prior to the start to ensure
time for any software downloads that may be required.
To access the live conference call via phone, dial 1-888-275-3514.
International callers may access the live call by dialing 706-679-1417.
The reference number to eter the call is 25925028.
The replay of the conference call may be accessed that same day after
8:00 p.m. Eastern Time, via the Internet, at www.XenoPort.com,
or via phone at 1-855-859-2056 for domestic callers, or 404-537-3406 for
international callers. The reference number to enter the replay of the
call is 25925028.
XenoPort, Inc. is a biopharmaceutical company focused on developing and
commercializing a portfolio of internally discovered product candidates
for the potential treatment of neurological disorders. XenoPort is
currently commercializing HORIZANT® (gabapentin enacarbil)
Extended-Release Tablets in the United States and developing its novel
fumaric acid ester product candidate, XP23829, as a potential treatment
for psoriasis and/or relapsing forms of multiple sclerosis. REGNITE®
(gabapentin enacarbil) Extended-Release Tablets is being marketed in
Japan by Astellas Pharma Inc. XenoPort's pipeline of product candidates
also includes potential treatments for patients with spasticity related
to spinal cord injury and Parkinson's disease. To learn more about
XenoPort, please visit the website at www.XenoPort.com.
XENOPORT, HORIZANT and REGNITE are registered trademarks of XenoPort,
[ Back To TMCnet.com's Homepage ]